On December 23, 2020, the US Trade Representative (USTR) posted on its website an advance copy of a notice of product exclusion extensions and additional modifications to be published in the Federal Register. In prior notices, the USTR modified the action in the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address the COVID-19 outbreak. On…